Peter A Campochiaro1, Dennis M Marcus2, Carl C Awh3, Carl Regillo4, Anthony P Adamis5, Vladimir Bantseev5, Yawen Chiang5, Jason S Ehrlich6, Signe Erickson7, William D Hanley8, Joshua Horvath5, Katie F Maass5, Natasha Singh5, Fan Tang5, Giulio Barteselli5. 1. The Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: pcampo@jhmi.edu. 2. Southeast Retina Center, Augusta, Georgia. 3. Tennessee Retina, Nashville, Tennessee. 4. Retina Service, Wills Eye Hospital, Philadelphia, Pennsylvania. 5. Genentech, Inc., South San Francisco, California. 6. Genentech, Inc., South San Francisco, California, at the time the work was completed; currently at Kodiak Sciences Inc., Palo Alto, California. 7. Genentech, Inc., South San Francisco, California, at the time the work was completed. 8. Genentech, Inc., South San Francisco, California, at the time the work was completed; currently at Seattle Genetics, Bothell, Washington.
Abstract
PURPOSE: To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration (nAMD) treatment. DESIGN: Phase 2, multicenter, randomized, active treatment-controlled clinical trial. PARTICIPANTS: Patients diagnosed with nAMD within 9 months who had received 2 or more prior anti-vascular endothelial growth factor intravitreal injections and were responsive to treatment. METHODS: Patients were randomized 3:3:3:2 to receive the PDS filled with ranibizumab 10 mg/ml, 40 mg/ml, 100 mg/ml, or monthly intravitreal ranibizumab 0.5-mg injections. MAIN OUTCOME MEASURES: Time to first implant refill assessed when the last enrolled patient completed the month 9 visit (primary efficacy end point), improvement in best-corrected visual acuity (BCVA) and central foveal thickness (CFT), and safety. RESULTS: The primary analysis population was 220 patients, with 58, 62, 59, and 41 patients in the PDS 10-mg/ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively. Median time to first implant refill was 8.7, 13.0, and 15.0 months in the PDS 10-mg/ml, PDS 40-mg/ml, and PDS 100-mg/ml arms, respectively. At month 9, the adjusted mean BCVA change from baseline was ‒3.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, ‒0.5 ETDRS letters, +5.0 ETDRS letters, and +3.9 ETDRS letters in the PDS 10-mg/ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively. At month 9, the adjusted mean CFT change from baseline was similar in the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg arms. The optimized PDS implant insertion and refill procedures were generally well tolerated. After surgical procedure optimization, postoperative vitreous hemorrhage rate was 4.5% (7/157; 1 event classified as serious). There was no evidence of implant clogging. CONCLUSIONS: In the phase 2 Ladder trial, the PDS was generally well tolerated and demonstrated a dose response across multiple end points in patients with nAMD. The PDS 100-mg/ml arm showed visual and anatomic outcomes comparable with monthly intravitreal ranibizumab 0.5-mg injections but with a reduced total number of ranibizumab treatments. The PDS has the potential to reduce treatment burden in nAMD while maintaining vision.
RCT Entities:
PURPOSE: To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration (nAMD) treatment. DESIGN: Phase 2, multicenter, randomized, active treatment-controlled clinical trial. PARTICIPANTS: Patients diagnosed with nAMD within 9 months who had received 2 or more prior anti-vascular endothelial growth factor intravitreal injections and were responsive to treatment. METHODS:Patients were randomized 3:3:3:2 to receive the PDS filled with ranibizumab 10 mg/ml, 40 mg/ml, 100 mg/ml, or monthly intravitreal ranibizumab 0.5-mg injections. MAIN OUTCOME MEASURES: Time to first implant refill assessed when the last enrolled patient completed the month 9 visit (primary efficacy end point), improvement in best-corrected visual acuity (BCVA) and central foveal thickness (CFT), and safety. RESULTS: The primary analysis population was 220 patients, with 58, 62, 59, and 41 patients in the PDS 10-mg/ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively. Median time to first implant refill was 8.7, 13.0, and 15.0 months in the PDS 10-mg/ml, PDS 40-mg/ml, and PDS 100-mg/ml arms, respectively. At month 9, the adjusted mean BCVA change from baseline was ‒3.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, ‒0.5 ETDRS letters, +5.0 ETDRS letters, and +3.9 ETDRS letters in the PDS 10-mg/ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively. At month 9, the adjusted mean CFT change from baseline was similar in the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg arms. The optimized PDS implant insertion and refill procedures were generally well tolerated. After surgical procedure optimization, postoperative vitreous hemorrhage rate was 4.5% (7/157; 1 event classified as serious). There was no evidence of implant clogging. CONCLUSIONS: In the phase 2 Ladder trial, the PDS was generally well tolerated and demonstrated a dose response across multiple end points in patients with nAMD. The PDS 100-mg/ml arm showed visual and anatomic outcomes comparable with monthly intravitreal ranibizumab 0.5-mg injections but with a reduced total number of ranibizumab treatments. The PDS has the potential to reduce treatment burden in nAMD while maintaining vision.
Authors: Sean F Hackett; Jie Fu; Yoo Chun Kim; Hiroki Tsujinaka; Jikui Shen; Raquel Lima E Silva; Mahmood Khan; Zibran Hafiz; Tao Wang; Matthew Shin; Nicole M Anders; Ping He; Laura M Ensign; Justin Hanes; Peter A Campochiaro Journal: Biomaterials Date: 2020-03-04 Impact factor: 12.479
Authors: Jason Yim; Reena Chopra; Terry Spitz; Jim Winkens; Annette Obika; Christopher Kelly; Harry Askham; Marko Lukic; Josef Huemer; Katrin Fasler; Gabriella Moraes; Clemens Meyer; Marc Wilson; Jonathan Dixon; Cian Hughes; Geraint Rees; Peng T Khaw; Alan Karthikesalingam; Dominic King; Demis Hassabis; Mustafa Suleyman; Trevor Back; Joseph R Ledsam; Pearse A Keane; Jeffrey De Fauw Journal: Nat Med Date: 2020-05-18 Impact factor: 53.440
Authors: Hong Xin; Nilima Biswas; Pin Li; Cuiling Zhong; Tamara C Chan; Eric Nudleman; Napoleone Ferrara Journal: Proc Natl Acad Sci U S A Date: 2021-05-25 Impact factor: 11.205
Authors: Rehan M Hussain; Bilal A Shaukat; Lauren M Ciulla; Audina M Berrocal; Jayanth Sridhar Journal: Drug Des Devel Ther Date: 2021-06-21 Impact factor: 4.162
Authors: Maximilian Pfau; Soumya Sahu; Rawan Allozi Rupnow; Kathleen Romond; Desiree Millet; Frank G Holz; Steffen Schmitz-Valckenberg; Monika Fleckenstein; Jennifer I Lim; Luis de Sisternes; Theodore Leng; Daniel L Rubin; Joelle A Hallak Journal: Transl Vis Sci Technol Date: 2021-06-01 Impact factor: 3.283